title: [Update on new antithrombotic treatments].
abstract: Update on new antithrombotic treatments Antithrombotic treatments are frequently prescribed in different clinical situations. Classical anticoagulants have some disadvantages. New anticoagulants have emerged recently. Fondaparinux is now prescribed for both prophylaxis and treatment of venous thromboembolism. Two drugs are particularly interesting: rivaroxaban and dabigatran. Concerning the new antiplatelet agents, many molecules such as prasugrel, ticagrelor, cangrelor, SCH530348 or terutroban have appeared recently. They are directed either to the P2Y12 receptor or to other original targets. Studies have shown an increased bleeding risk for some of them as well as unexpected side effects. In the next future, these new molecules could allow a more individualised prescription of antithrombotic agents.
authors.affiliation: Unité D'Hémostase Service, d'angiologie et d'hémostase, Département de médicine interne, HUG, Genève. francoise.boehlen@hcuge.ch
authors.forename: F
authors.initials: F
authors.lastname: Boehlen
authors.forename: Y
authors.initials: Y
authors.lastname: Tirefort-Dimitrova
authors.forename: P
authors.initials: P
authors.lastname: de Moerloose
authors.forename: P
authors.initials: P
authors.lastname: Fontana
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors